PD-1 Inhibitor Improves Outcomes in NHL Subtype

Treatment with the PD-1 inhibitor toripalimab plus radiation therapy improved outcomes in patients with a subtype of non-Hodgkin lymphoma, new data show.

Related Keywords

Madrid ,Spain ,Peking ,Beijing ,China ,Chengdu ,Sichuan ,France ,Ming Jiang ,Guangxi ,Gansu ,Olivier Casasnovas ,Cancer Center ,European Society Of Medical Oncology ,University Hospital Francois Mitterrand In Dijon ,European Society ,Medical Oncology ,West China School ,West China Hospital ,Sichuan University ,Ning Lou ,Cancer Hospital Chinese Academy ,Medical Sciences ,Peking Union Medical College ,University Hospital Francois Mitterrand ,Non Hodgkins Lymphoma ,Radiation Oncology ,Lymphoma ,Malignant Lymphoma ,Genomics ,Genomic Medicine ,Edicine Genomic ,Chemotherapy ,Hospitals ,Thyroid Disorder ,Cancer ,Alignant Neoplasia ,Arcinoma ,Dna Sequencing ,Genetics ,Oncological Medicine ,Tumor ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Hypothyroidism ,Clinical Research ,Clinica ,